

ALLIGATOR BIOSCIENCE ANNOUNCES PUBLICATION HIGHLIGHTING ATOR-1017 PRECLINICAL DATA IN THE SCIENTIFIC JOURNAL "CANCER IMMUNOLOGY, IMMUNOTHERAPY"

- ATOR-1017, a potential best-in-class 4-1BB monoclonal antibody, demonstrates an excellent preclinical profile with a unique binding site on 4-1BB
- Preclinical data demonstrate ATOR-1017's strong safety profile and potent therapeutic anti-tumor effect *in vivo* both as monotherapy and in combination with anti-PD-1 treatment
- ATOR-1017 demonstrated excellent clinical profile as a potential best-in-class 4-1BB monoclonal antibody in recent Phase 1 dose-escalation study
- The data presented in the manuscript provides a strong preclinical foundation for further clinical development of ATOR-1017

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the publication of a scientific article highlighting the 4-1BB FcγR-conditional agonist antibody ATOR-1017, which is being developed as a tumor-directed therapy for advanced/metastatic cancer.

The publication in the journal *Cancer Immunology, Immunotherapy* demonstrates how the design, detailed binding epitope (binding site) on 4-1BB and molecular properties of ATOR-1017 translate into very potent activity both *in vitro* and *in vivo*, as monotherapy and in combination with anti-PD-1 treatment, while being well tolerated in preclinical models.

ATOR-1017 binds to a unique epitope on 4-1BB enabling the activation of T cells, including cells with an exhausted phenotype, and NK cells, in a cross-linking dependent, FcγR-conditional manner. This translates into a tumor-directed and potent anti-tumor therapeutic effect *in vivo*, which is further enhanced with anti-PD-1 treatment.

The full article, entitled "**ATOR-1017, an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1**", is available online [via this link](#).

*"The publication of this article in the renowned scientific journal Cancer Immunology, Immunotherapy is an important recognition of our research into 4-1BB as a target for cancer immunotherapy," said **Søren Bregenholt, CEO of Alligator Bioscience**. "The first generation of 4-1BB agonists were limited by poor efficacy and unacceptable safety profiles but the preclinical data presented in this article, and the results of our recent Phase 1 dose-escalation study, demonstrate how ATOR-1017 is both a potent 4-1BB agonist and a safe and well tolerated drug candidate with a significant therapeutic potential."*

In September 2022, **Alligator announced that its Phase 1 open-label dose-escalation study of ATOR-1017** in patients with histologically confirmed, advanced, and/or refractory solid cancer (NCT04144842) had successfully met its primary objective to investigate the safety and tolerability of ATOR-1017 at therapeutic doses. ATOR-1017 demonstrated excellent safety and tolerability at doses up to 900 mg and stable disease as the best tumor response confirmed its **previously reported indications on clinical benefit**.

For further information, please contact:

Søren Bregenholt, CEO

E-mail: soren.bregenholt@alligatorbioscience.com

Phone: +46 (0) 46 540 82 00

LifeSci Advisors

Investor Relations

Guillaume van Renterghem

E-mail: gvanrenterghem@lifesciadvisors.com

Phone: +41 (0) 76 735 01 31

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's portfolio includes several promising drug candidates, with the CD40 agonist mitazalimab as its key asset. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc.

Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.

For more information, please visit alligatorbioscience.com.

Attachments

Alligator Bioscience Announces Publication Highlighting ATOR-1017 Preclinical Data in the Scientific Journal "Cancer Immunology, Immunotherapy"